CereVasc, Inc. announced the randomization of the first patient in the multicenter STRIDE clinical trial of the company’ ...

A recent study published in the Journal of Stroke and Cerebrovascular Diseases identified fibrinogen as a potential ...

Background We aimed to describe neuroimaging features, clinical profiles and long-term outcomes in patients with iatrogenic cerebral amyloid angiopathy (iCAA). Methods We performed a systematic ...

Algernon NeuroScience has appointed Dr. Sandor Nardai as the Principal Investigator for its upcoming randomized, double-blind, placebo-controlled Phase 2a DMT study of 40 stroke patients in Europe.

From quaternary hospitals nationally recognized for their care, to convenient doctors’ offices within the community, the Institute for Neurology and Neurosurgery is able to provide exceptional, ...

To address these limitations, the research team developed a cerebrovascular-specific bioink using "decellularized extracellular matrix" (CBVdECM), derived from porcine brain and blood vessels.